![]() ![]() Federal Trade Commission (FTC) launched an investigation in 2022 to look into potential bid-rigging among baby formula manufacturers, including Abbott Laboratories, on state contracts. ![]() Using insights from the NASEM study, the FDA will work on a long-term national strategy. infant formula market, published in March 2023. ![]() Under the 2022 Food and Drug Omnibus Reform Act, the FDA was tasked to create an immediate strategy for enhancing the resilience of the U.S. Once completed, NASEM will report its findings to both Congress and the FDA. and foreign markets like the European Union. It will also examine the influences affecting market competition and regulatory variations between the U.S. The study aims to understand the pre and post-COVID-19 market changes, including aspects like the Abbott recall incident in February 2022. This investigation will scrutinize current market conditions, manufacturing diversity, product types, production capacities, and domestic vs. June 1, 2023: The FDA announced that the National Academies of Sciences, Engineering, and Medicine (NASEM) will carry out an independent inquiry into the U.S. economy have created a very acute shortage of infant formula, resulting in empty shelves and understandably stressed and concerned parents. The supply chain problems that are currently hampering the U.S. Parents of new babies in many parts of the country are having a hard time finding infant formulas such as Similac and Enfamil in June 2022. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |